Efficacy of BMS-214662 against Ph⁺ versus Ph⁻ LTC-IC. (A) Results of LTC-IC assay in CML (n = 3). The addition of BMS-214662 to either IM or dasatinib significantly reduced the number of colonies compared with either drug alone (P = .032 and P = .027, respectively). BMS-214662 also significantly reduced the number of colonies compared with the no drug control (P = .028 for BMS-214662 and BMS-214662 + IM arm and P = .031 for BMS-214662 + dasatinib arm). (B) Results of LTC-IC assay in normal donors (n = 3). There was a nonsignificant increase in LTC-IC in the IM and dasatinib only arms. In the BMS-214662-containing arms, there was a nonsignificant reduction in LTC-IC compared with control (P = .079-.29).